Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03225547 | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | terminated | Phase 2 | 24 | University of ChicagoOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05171166 | Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. | terminated | Phase 2 / Phase 3 | 18 | Peking UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05860296 |
| Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers |
| terminated |
| Phase 1 / Phase 2 |
| 36 |
| SignalChem Lifesciences CorporationINDUSTRY |
| 2 |
| Dec 18, 2025 |
| clinicaltrials |
| NCT06359379 | Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter | terminated | Phase 2 | 30 | Shuttle Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03758417 | A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma(CARTIFAN-1) | terminated | Phase 2 | 123 | Nanjing Legend Biotech Co.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT04688658 | Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma | terminated | Phase 1 / Phase 2 | 13 | John KirkwoodOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT04445064 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.(HN1901) | terminated | Phase 2 | 17 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04765709 | Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC(BRIDGE) | terminated | Phase 2 | 10 | Mario Negri Institute for Pharmacological ResearchOTHER | 3 | Dec 16, 2025 | clinicaltrials |
| NCT05313009 | Tarlox and Sotorasib in Patients With KRAS G12C Mutations | terminated | Phase 1 / Phase 2 | 5 | Medical University of South CarolinaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05998447 | GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | terminated | Phase 2 | 10 | Genome & CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05317936 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05454358 | Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP | terminated | Phase 2 / Phase 3 | 12 | Fudan UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT02772562 | Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy | terminated | Phase 2 | 33 | Medical University of South CarolinaOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT03698552 | ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT06851442 | Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 8 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 12, 2025 | clinicaltrials |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | terminated | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04176497 | PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study | terminated | Phase 2 | 8 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06818305 | Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT(EmFin-Nx) | terminated | Phase 2 | 10 | Jinling Hospital, ChinaOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | terminated | Phase 2 | 4 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05583110 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer(TrasTUCAN) | terminated | Phase 2 | 13 | Spanish Breast Cancer Research GroupOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT01570868 | Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | terminated | Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT03595683 | Pembrolizumab and EDP1503 in Advanced Melanoma | terminated | Phase 2 | 8 | University of ChicagoOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05114213 | MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC(MASPAC) | terminated | Phase 2 | 9 | Ludwig-Maximilians - University of MunichOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05361057 | Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients | terminated | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05918055 | Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04276376 | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors(ARIANES) | terminated | Phase 2 | 130 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab(NIRADO) | terminated | Phase 2 | 51 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05180006 | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy(BIS-Program) | terminated | Phase 2 | 33 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05464836 | Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03284957 | Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer(AMEERA-1) | terminated | Phase 1 / Phase 2 | 136 | SanofiINDUSTRY | 10 | Nov 24, 2025 | clinicaltrials |
| NCT01316523 | Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma | terminated | Phase 2 | 30 | University of California, DavisOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02706353 | APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT05496569 | TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma | terminated | Phase 2 | 26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05954143 | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 11 | Bolt Biotherapeutics, Inc.INDUSTRY | 2 | Nov 20, 2025 | clinicaltrials |
| NCT04370509 | Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery | terminated | Phase 2 | 6 | University of California, San FranciscoOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04854499 | Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma(ELEVATE HNSCC) | terminated | Phase 2 | 193 | Gilead SciencesINDUSTRY | 11 | Nov 19, 2025 | clinicaltrials |
| NCT04549428 | Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC | terminated | Phase 2 | 12 | Oncology Institute of Southern SwitzerlandOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04396535 | Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 10 | Mayo ClinicOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04635059 | Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer(BLAST) | terminated | Phase 2 | 6 | Medical College of WisconsinOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04844970 | Anamorelin Study for Advanced Pancreatic Cancer | terminated | Phase 2 | 4 | Lahey ClinicOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | terminated | Phase 2 | 166 | SOTIO Biotech AGINDUSTRY | 9 | Nov 17, 2025 | clinicaltrials |
| NCT05525286 | Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma(CLAUDIO-01) | terminated | Phase 1 / Phase 2 | 31 | SOTIO Biotech a.s.INDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT04106492 | Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 53 | Shasqi, Inc.INDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT04024436 | A Study of TAS-120 in Patients With Metastatic Breast Cancer | terminated | Phase 2 | 64 | Taiho Oncology, Inc.INDUSTRY | 7 | Nov 13, 2025 | clinicaltrials |
| NCT03498612 | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | terminated | Phase 2 | 9 | University of WashingtonOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03979508 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer | terminated | Phase 2 | 26 | Mayo ClinicOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05119335 | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 120 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05935748 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | terminated | Phase 2 | 18 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 23, 2025source: clinicaltrials